5 result(s) for 'Automated IHC Workflow'
1 - 5 of 5 results for 'Automated IHC Workflow'
Sort by
Show
SEATTLE, USA and MELBOURNE, AUSTRALIA. March 1st Leica Biosystems continues to advance its relationship with NanoString Technologies Inc., supporting translational research to build confidence in reproducibility and throughput while minimizing manual steps and reducing hands-on time with the release of the fully automated GeoMx RNA protocol on BOND RX and BOND RXm research staining systems.
“This fully automated protocol not only increased our ability to get more slides done in a week but also increased the quality of the data coming off of our instrument by reducing variability between runs,” said Carlee Hemphill, lead scientist, CDx Labcorp Drug Development.
NanoString's GeoMx Digital Spatial Profiler uses spatial images, chemistry, and workflow to enable high-plex profiling ...
Probes for the CE-IVD marked kit now available for clinical use.
Leica Biosystems, a global leader in pathology workflow solutions, previously partnered with Bio-Techne to create a fully automated, walk-away solution on the BOND-III IHC and ISH stainer, for use in automating RNA ISH. Now, Bio-Techne has registered probes for clinical utility within Europe for use with the RNAscope detection kit from Leica Biosystems. The CE-IVD marked RNAscope ISH Probe High Risk HPV is intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to aid in the identification of high-risk human papillomavirus (HPV).
RNAscope in situ hybridization is a highly sensitive and specific spatial biology technology that enables users to visualize and localize biomarker expr...
San Diego, CA – November 8, 2022. Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, has acquired Cell IDx, Inc., a leader in multiplexed tissue profiling. Founded in 2012 and headquartered in San Diego, California, Cell IDx provides multiplex staining panels, tissue staining, and imaging and analysis services.
Cell IDx’s UltraPlex technology allows simultaneous detection of multiple biomarkers in many immunoassays through fluorescent and chromogenic multiplex immunohistochemistry (“IHC”) staining technology, and automated chromogenic detection of multiple markers on Leica Biosystems’ BOND RX fully automated research stainer. Together, UltraPlex and BOND RX with high throughput imaging allows researchers to detect three or more ...
The BOND MMR Antibody Panel is now available for clinical use on BOND-III and BOND-MAX Immunohistochemistry (IHC) automated instruments.
NEWCASTLE, UK – Leica Biosystems today announced the US Food and Drug Administration (FDA) 510(k) clearance of the BOND MMR Antibody Panel, providing customers with a high-performing IHC Mismatch Repair (MMR) option when screening colorectal cancer patients for the identification of probable Lynch syndrome.
“Pathologists can utilize the Leica Biosystems BOND MMR panel on the BOND-III for clear, accurate assessment of mismatch repair protein status in only 2.5 hours,” said Dr. Robert Monroe, Chief Medical Officer at Leica Biosystems. “With this panel, clinicians can feel increased confidence in their MMR results.” Colorectal cancer (CRC) is the...
by Chad Salinas, Vice President, AI and Machine Learning
Artificial Intelligence is exponentially increasing its impact on healthcare. As deep learning is mastering computer vision tasks, its application to digital pathology is natural, with the promise of aiding in routine reporting and standardizing results across trials. 1
Physicians recognize the potential of AI in pathology, with one global survey documenting nearly 75% of respondents reporting interest or excitement in AI as a diagnostic tool to facilitate improvements in workflow efficiency and quality assurance in pathology.2 This finding is, in part, a recognition of the increasing complexity associated with practicing pathology: complicated workflows3 coupled with global pathology workforce shortages4,5 impact patholo...